Social Anxiety Disorder Clinical Trial
Official title:
Examining the Effects of a Combined Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) for Social Anxiety Disorder
This RCT examines the effectiveness of Attention Bias Modification Treatment (ABMT) as an
augment to Cognitive-Behavioral Group Treatment (CBGT) for Social Anxiety Disorder (SAD) in
adults. It is expected that ABMT vs. control training condition would achieve better
therapeutic outcomes as indicated reduction in symptoms.
Participants from three groups (estimated 40 patients) will be offered to participate in the
study
Outpatients seeking treatment for Social Anxiety Disorder (SAD) at Geha anxiety-disorders
clinic will be randomized into two groups (ABMT+CBGT; placebo control+CBGT). One group will
undergo an Attention Bias Modification Treatment (ABMT) aimed at diverting attention away
from socially-threatening stimuli. The second group will receive a placebo-control not
designed to affect attention. Both groups will also undergo a standard Cognitive-Behavioral
Group Treatment (CBGT) comprising 18 weekly sessions of 1.5-hr duration (along the lines of
Heimberg, Juster, Hope & Mattia 1995 and Clark & Wells 1995). Symptoms and attention bias
measures will be taken at three time points: Pre-treatment, Post-treatment,and at 3-month
follow-up.
The study includes the following steps: a) initial assessment of participants'
psychopathology and symptom levels; b) attention bias measurement; c) 8 sessions of
ABMT/placebo control delivered as part of the CBGT sessions; d) two booster ABMT/Placebo
treatments will be delivered at sessions 13 and 16 of the CBGT protocol. e) post-treatment
assessment will include symptom and attention bias assessments. Finally, f) a three-month
follow up assessment.
The goal of the study is to to test the effectiveness of ABMT as an add-on to established
CBGT protocol for social anxiety disorder.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485888 -
Flushing in Social Anxiety Disorder on Cipralex
|
Phase 2 | |
Completed |
NCT00773162 -
Flushing in Social Anxiety Disorder on Seroquel
|
Phase 3 |